• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

NSAID approved for cataract pain

Article

After a priority 6-month review, the FDA approved nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories), a novel nonsteroidal anti-inflammatory prodrug, for the treatment of pain and inflammation associated with cataract surgery.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
Related Content
FDA approves first biosimilar product for retinal diseases

Making the grade: FDA approves first biosimilar product for retinal diseases

Article
Advancement in TED treatment is a bright spot

Advancement in TED treatment is a bright spot

Article
Comparable conscious sedation methods address individual patient needs

Comparable conscious sedation methods address individual patient needs

Article
Investigators uncover health care disparities among US patients

Investigators uncover health care disparities among US patients

Article
Investigators zoom in on future of dry eye treatment

Investigators zoom in on future of dry eye treatment

Article
Analyzing opioid prescription patterns of US retina specialists

Analyzing opioid prescription patterns of US retina specialists

Article
© 2024 MJH Life Sciences

All rights reserved.